Team:Imperial College London/Project Overview

From 2009.igem.org

(Difference between revisions)
(Project Overview)
(Project Overview)
Line 10: Line 10:
<script type="text/javascript" src="http://biocyc.org/overLIB/Mini/overlib_exclusive_mini.js"></script>
<script type="text/javascript" src="http://biocyc.org/overLIB/Mini/overlib_exclusive_mini.js"></script>
<script type="text/javascript" src="http://biocyc.org/overLIB/Mini/overlib_positioncap_mini.js"></script>
<script type="text/javascript" src="http://biocyc.org/overLIB/Mini/overlib_positioncap_mini.js"></script>
 +
 +
 +
<p class="ecoparagraph">
 +
<map name="MAP91791">
 +
<area coords="147,18,177,35" onmouseover="return overlib('H-NS transcriptional dual regulator represses transcription from associated promoter<br>The exact location of this binding site is unknown or not specified.<br><b>Evidence:</b> Gene expression analysis<br>The nature of binding of this protein is not well known.');" onmouseout="return nd();">
 +
<area coords="0,74,32,91" onmouseover="return overlib('RcsAB transcriptional dual regulator activates transcription from associated promoter<br><b>Distance to transcription start site:</b> -166.5 (ranging from -173 to -160)<br><b>Evidence:</b> Gene expression analysis [Ebel99], Automated inference based on similarity to consensus sequences [Ebel99]');" onmouseout="return nd();">
 +
<area coords="34,74,66,91" onmouseover="return overlib('RcsAB transcriptional dual regulator activates transcription from associated promoter<br><b>Distance to transcription start site:</b> -125.5 (ranging from -132 to -119)<br><b>Evidence:</b> Binding of cellular extracts, Site mutation [Wehland00], Binding of purified proteins [Wehland00]');" onmouseout="return nd();">
 +
<area coords="147,0,184,17" onmouseover="return overlib('GadE transcriptional activator activates transcription from associated promoter<br>The exact location of this binding site is unknown or not specified.<br><b>Evidence:</b> Binding of purified proteins [Hommais04], Gene expression analysis [Hommais04]');" onmouseout="return nd();">
 +
<area coords="104,60,165,91" onmouseover="return overlib(' <b>Gene:</b>  rcsA    EG10820    b1951    ECK1949<br><b>Synonyms:</b> cpsR<br><b>Location:</b> 2,021,992 -> 2,022,615  <br> <b>Product:</b> positive DNA-binding transcriptional regulator of capsular polysaccharide synthesis, activates its own expression, subunit of RcsAB transcriptional dual regulator');" onmouseout="return nd();">
 +
<area coords="24,0,184,108" onmouseover="return overlib('<b>Operon:</b> rcsAp (Experim. ev.)  <BR><b>Tr.Activators:</b> (GadE RcsAB) <BR><b>Tr.Inhibitors:</b> (Hns)');" onmouseout="return nd();">
 +
<area coords="0,0,184,108"  onmouseover="return overlib('<b>Operon</b>: rcsA');" onmouseout="return nd();">
 +
</map>
 +
<img src="https://static.igem.org/mediawiki/2009/8/89/Op8.gif" usemap="#MAP91791" border="0">
 +
</p>
 +
 +
 +
</html>
 +

Revision as of 11:06, 16 October 2009

Project Overview

The inspiration behind The E.ncapsulator was the inherent difficulty in delivering protein pharmaceuticals to the gut. Due to the delicate nature of proteins and the highly acidic environment present in the stomach, protein molecules are readily broken down - making oral drug delivery of protein pharmaceuticals impossible. The E.ncapsulator is a novel protein manufacture and delivery platform designed to overcome these difficulties.


<map name="MAP91791"> <area coords="1,18,50,35" onmouseover="return overlib('Module 1 is our protein production module');" onmouseout="return nd();"></map> <img src="http://i691.photobucket.com/albums/vv271/dk806/TheOverviewPicDK.png" usemap="#MAP91791" border="0">


</html>

Modularity is key to the design of The E.ncapsulator. In order to simplify the system, and to increase reusability, the system has been divided into 3 active modules. These are as follows:

  1. Module 1: Protein Production
    • The first module involves engineering E.coli to synthesise the protein drug of interest to sufficient quantities.
  2. Module 2: Encapsulation
    • E.coli coats itself in a protective layer of colanic acid to form The E.ncapsulator. This protective capsule is what protects the biopharmaceutical against the harsh acidic environment of the stomach. This module also codes for the production of a protective sugar, trehalose, which will protect the protein of interest under storage conditions, and will allow for freeze drying.
  3. Module 3: Genome Deletion
    • The third module, genome deletion, is composed of a ‘suicide trigger’ mechanism that destroys the genetic material of the bacteria, leaving the cell membrane left intact. This killing strategy means the biopharmaceutical remains protected even after the cell is dead.
  4. Release
    • Once in the small intestine, the capsule will be naturally degraded by enzymes present, thereby releasing the designed biopharmaceutical to the gut micro biota where it can carry out its intended function.


In order to demonstrate the feasability of The E.ncapsulator as a new drug delivery platform, we have chosen to program the system to manufacture 2 enzyme pharmaceuticals, cellulase and PAH.


Continue and start the project tour




Pushed for time? These links may be useful to quickly browse our results and achievements:

Major Results
Submitted Parts
Achievements
Pill Manufacture
Genealogy
 

Mr. Gene   Geneart   Clontech   Giant Microbes